Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.59 |
| ▸ | PREP | P48147 | 1/20 | 0.57 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.56 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26094394 | 1.00 | DPP4 (0.59) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL5314581 | 1.00 | DPP4 (0.59) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL2679489 | 0.94 | DPP4 (0.54) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL6967964 | 0.94 | DPP4 (0.54) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL5480695 | 0.94 | DPP4 (0.54) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL14834279 | 0.87 | — | — | |
| SCHEMBL16054584 | 0.87 | — | — | |
| SCHEMBL3362068 | 0.83 | DPP4 (0.59) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL14450652 | 0.82 | DPP4 (0.57) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL8256353 | 0.82 | DPP4 (0.57) | DPP4PREPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | claimed |
| EP-3474901-B1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B V (NL) | 2025-08-06 | — | — | EP | disclosed |
| US-12186405-B2 | Cleavable tetrazine used in bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2025-01-07 | — | — | US | disclosed |
| WO-2024035771-A2 | ULK3 INHIBITORS AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20230144534-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| US-11617799-B2 | Cleavable tetrazine used in bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-04-04 | — | — | US | disclosed |
| CN-108884068-A | 1- cyano-pyrolidin derivative as DUB inhibitor | 特殊治疗有限公司 | 2018-11-23 | — | — | CN | disclosed |
| EP-2822548-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | University Of Virginia Patent Foundation (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009146112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SPHINGOSINE KINASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-12-03 | — | — | WO | disclosed |
| EP-1689391-B1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | NOVARTIS AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| US-7166586-B2 | Sulfonamide lactam inhibitors of FXa and method | BRISTOL MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1689391-A2 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005021519-A2 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | NOVARTIS AG (CH) | 2005-03-10 | — | — | WO | disclosed |
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | O'CONNOR STEPHEN P (US) | 2004-09-23 | — | — | US | disclosed |
| US-6555542-B1 | Factor Xa (FXa); useful as anticoagulants in the treatment of cardiovascular diseases associated with thrombosis | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | DPP4 2685/4885PREP 2820/4885DPP8 4194/4885 |
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | STS, SULT1E1, F8 | DPP4 2028/4885PREP 302/4885DPP8 1600/4885 |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | PI4KA, IP6K3, PHOSPHO1 | DPP4 2254/4885PREP 2999/4885DPP8 2033/4885 |
| US-20230144534-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | KIT, TPSB2, BTD | DPP4 169/4885PREP 94/4885DPP8 65/4885 |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | DPP4 2354/4885PREP 2874/4885DPP8 4077/4885 |
| US-11617799-B2 | Cleavable tetrazine used in bio-orthogonal drug activation | KIT, TPSB2, BTD | DPP4 169/4885PREP 94/4885DPP8 65/4885 |
| US-12186405-B2 | Cleavable tetrazine used in bio-orthogonal drug activation | KIT, TPSB2, BTD | DPP4 169/4885PREP 94/4885DPP8 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.